Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer
Collectively, these findings suggest that CCTR offers superior predictive information compared to KI and MI alone with respect to long-term outcomes from adjuvant chemotherapy in patients with TNBC that may guide treatment decision making.
Authors
- Emiel A. M. Janssen (ORCID: https://orcid.org/0000-0002-7760-5396)
- Padmashree C.G. Rida
- Jeanne Kowalski (ORCID: https://orcid.org/0000-0003-3458-3024)
- Ritu Aneja (ORCID: https://orcid.org/0000-0003-4489-5320)
- Emad A. Rakha (ORCID: https://orcid.org/0000-0002-5009-5525)
- Geetanjali Saini (ORCID: https://orcid.org/0000-0002-3502-2491)
- Qi Xu (ORCID: https://orcid.org/0000-0002-4646-6936)
- Ian Ogilvie Ellis (ORCID: https://orcid.org/0000-0001-5292-8474)
- Mohammed A. Aleskandarany
- Manali Rupji
- Andrew R. Green (ORCID: https://orcid.org/0000-0002-0488-5913)
- Shristi Bhattarai (ORCID: https://orcid.org/0000-0002-6639-057X)
- Kristín Jónsdóttir
- He Chao
Institutions
- Livestrong Foundation (US)
- University of Nottingham (GB)
- Emory University (US)
- Kennesaw State University (US)
- Georgia State University (US)
- University of Derby (GB)
- Stavanger University Hospital (NO)
- University of Alabama at Birmingham (US)
- Molecular Theranostics (United States) (US)
- The University of Texas at Austin (US)
Publication Details
- Journal
- BJC Reports
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1038/s44276-024-00097-z
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.29
Funders
- Emory University
- National Institutes of Health
- Winship Cancer Institute
- National Cancer Institute